These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 12623359

  • 1. Antivascular therapy of cancer: DMXAA.
    Baguley BC.
    Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR.
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [Abstract] [Full Text] [Related]

  • 10. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L, Kestell P, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
    Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC.
    Br J Cancer; 2002 Jun 17; 86(12):1937-42. PubMed ID: 12085190
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM.
    Br J Cancer; 1999 May 17; 80(5-6):716-23. PubMed ID: 10360649
    [Abstract] [Full Text] [Related]

  • 15. Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA.
    Barbera M, Kettunen MI, Caputo A, Hu DE, Gobbi S, Brindle KM, Carrara M.
    Int J Oncol; 2009 Jan 17; 34(1):273-9. PubMed ID: 19082498
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
    Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC.
    Clin Chim Acta; 2001 Dec 17; 314(1-2):159-66. PubMed ID: 11718691
    [Abstract] [Full Text] [Related]

  • 18. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
    Ching LM, Zwain S, Baguley BC.
    Br J Cancer; 2004 Feb 23; 90(4):906-10. PubMed ID: 14970872
    [Abstract] [Full Text] [Related]

  • 19. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM.
    Cancer Res; 1999 Feb 01; 59(3):633-8. PubMed ID: 9973211
    [Abstract] [Full Text] [Related]

  • 20. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Woon ST, Baguley BC, Palmer BD, Fraser JD, Ching LM.
    Oncol Res; 2002 Feb 01; 13(2):95-101. PubMed ID: 12392157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.